Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 6Leukemia, Myelomonocytic, Chronic 3Glioma 2Glioblastoma 2Cholangiocarcinoma 2Targeted Therapy 1Spinal Cord Neoplasms 1Oligodendroglioma 1Neoplasms 1Myeloproliferative Disorders 1Myeloid Malignancies 1Diffuse Intrinsic Pontine Glioma 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 111Radiotherapy 60Carboplatin 30Bevacizumab 30Magnetic Resonance Spectroscopy 28Carmustine 28Filgrastim 23Surgical Procedures, Operative 22Irinotecan 22Radiation 17Lomustine 16Vincristine 15Etoposide 15Specimen Handling 13Peripheral Blood Stem Cell Transplantation 13O(6)-benzylguanine 13Radiotherapy, Intensity-Modulated 12Procarbazine 11Erlotinib Hydrochloride 11Cyclophosphamide 11Chemotherapy, Adjuvant 11sargramostim 10Thiotepa 10Cisplatin 10Flucytosine 9Everolimus 9antineoplaston AS 2-1 8antineoplaston A10 8Granulocyte Colony-Stimulating Factor 8Vorinostat 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Astrocytoma × olutasidenib × Clear all
NCT06161974 2025-02-21

Study of Olutasidenib and Temozolomide in HGG

Rigel Pharmaceuticals

Phase 2 Recruiting
60 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡